Cargando…

Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin

BACKGROUND: The diagnosis of tuberculosis (TB) using smear microscopy has been based on testing two specimens: one spot and one early morning sputa. Recently, the World Health Organization (WHO) has recommended to replace, whenever possible, microscopy with GeneXpert® MTB/RIF performed on a single s...

Descripción completa

Detalles Bibliográficos
Autores principales: Massou, Faridath, Fandohan, Merlin, Wachinou, Ablo Prudence, Agbla, Schadrac Christin, Agodokpessi, Gildas, Rigouts, Leen, de Jong, Bouke Catherine, Affolabi, Dissou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454072/
https://www.ncbi.nlm.nih.gov/pubmed/34544371
http://dx.doi.org/10.1186/s12879-021-06676-6
_version_ 1784570413100040192
author Massou, Faridath
Fandohan, Merlin
Wachinou, Ablo Prudence
Agbla, Schadrac Christin
Agodokpessi, Gildas
Rigouts, Leen
de Jong, Bouke Catherine
Affolabi, Dissou
author_facet Massou, Faridath
Fandohan, Merlin
Wachinou, Ablo Prudence
Agbla, Schadrac Christin
Agodokpessi, Gildas
Rigouts, Leen
de Jong, Bouke Catherine
Affolabi, Dissou
author_sort Massou, Faridath
collection PubMed
description BACKGROUND: The diagnosis of tuberculosis (TB) using smear microscopy has been based on testing two specimens: one spot and one early morning sputa. Recently, the World Health Organization (WHO) has recommended to replace, whenever possible, microscopy with GeneXpert® MTB/RIF performed on a single specimen. However, as the bacterial load is higher in early morning specimens than in spot specimens, one could expect lower sensitivity of GeneXpert® MTB/RIF performed only on spot specimens. In this study, we compared results of GeneXpert® MTB/RIF on spot specimens versus early morning specimens, under programmatic conditions in Cotonou, Benin. METHODS: From June to September 2018, all sputa received from presumptive TB patients at the Supranational Reference Laboratory for Tuberculosis of Cotonou were included in the study. From each patient, two specimens were collected (one spot and one early morning) and GeneXpert® MTB/RIF was performed on both specimens. RESULTS: In total, 886 participants were included in the study, of whom 737 provided both sputa and 149 (16.8%) gave only the spot specimen. For the 737 participants who provided both sputa, GeneXpert® MTB/RIF was positive for both specimens in 152 participants; for three participants GeneXpert® MTB/RIF was positive on spot specimen but negative on morning specimen while for another three, the test was positive on morning specimen but negative on spot specimen. The overall percentage of agreement was excellent (99.2%) with a positive and negative percent agreement greater than 98%. CONCLUSION: For TB diagnosis under programmatic conditions in Cotonou, GeneXpert® MTB/RIF in spot specimens gave similar results with the test in morning specimens. Performing GeneXpert® MTB/RIF in both specimens did not significantly increase the number of cases detected. To avoid losing patients from the diagnostic cascade, it is preferable to test sputa produced at the time of the first visit at the health center. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06676-6.
format Online
Article
Text
id pubmed-8454072
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84540722021-09-21 Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin Massou, Faridath Fandohan, Merlin Wachinou, Ablo Prudence Agbla, Schadrac Christin Agodokpessi, Gildas Rigouts, Leen de Jong, Bouke Catherine Affolabi, Dissou BMC Infect Dis Research BACKGROUND: The diagnosis of tuberculosis (TB) using smear microscopy has been based on testing two specimens: one spot and one early morning sputa. Recently, the World Health Organization (WHO) has recommended to replace, whenever possible, microscopy with GeneXpert® MTB/RIF performed on a single specimen. However, as the bacterial load is higher in early morning specimens than in spot specimens, one could expect lower sensitivity of GeneXpert® MTB/RIF performed only on spot specimens. In this study, we compared results of GeneXpert® MTB/RIF on spot specimens versus early morning specimens, under programmatic conditions in Cotonou, Benin. METHODS: From June to September 2018, all sputa received from presumptive TB patients at the Supranational Reference Laboratory for Tuberculosis of Cotonou were included in the study. From each patient, two specimens were collected (one spot and one early morning) and GeneXpert® MTB/RIF was performed on both specimens. RESULTS: In total, 886 participants were included in the study, of whom 737 provided both sputa and 149 (16.8%) gave only the spot specimen. For the 737 participants who provided both sputa, GeneXpert® MTB/RIF was positive for both specimens in 152 participants; for three participants GeneXpert® MTB/RIF was positive on spot specimen but negative on morning specimen while for another three, the test was positive on morning specimen but negative on spot specimen. The overall percentage of agreement was excellent (99.2%) with a positive and negative percent agreement greater than 98%. CONCLUSION: For TB diagnosis under programmatic conditions in Cotonou, GeneXpert® MTB/RIF in spot specimens gave similar results with the test in morning specimens. Performing GeneXpert® MTB/RIF in both specimens did not significantly increase the number of cases detected. To avoid losing patients from the diagnostic cascade, it is preferable to test sputa produced at the time of the first visit at the health center. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06676-6. BioMed Central 2021-09-20 /pmc/articles/PMC8454072/ /pubmed/34544371 http://dx.doi.org/10.1186/s12879-021-06676-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Massou, Faridath
Fandohan, Merlin
Wachinou, Ablo Prudence
Agbla, Schadrac Christin
Agodokpessi, Gildas
Rigouts, Leen
de Jong, Bouke Catherine
Affolabi, Dissou
Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin
title Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin
title_full Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin
title_fullStr Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin
title_full_unstemmed Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin
title_short Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin
title_sort spot specimen testing with genexpert mtb/rif results compared to morning specimen in a programmatic setting in cotonou, benin
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454072/
https://www.ncbi.nlm.nih.gov/pubmed/34544371
http://dx.doi.org/10.1186/s12879-021-06676-6
work_keys_str_mv AT massoufaridath spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin
AT fandohanmerlin spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin
AT wachinouabloprudence spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin
AT agblaschadracchristin spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin
AT agodokpessigildas spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin
AT rigoutsleen spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin
AT dejongboukecatherine spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin
AT affolabidissou spotspecimentestingwithgenexpertmtbrifresultscomparedtomorningspecimeninaprogrammaticsettingincotonoubenin